Skip Ribbon Commands
Skip to main content

e-ULTIMASTER Trial

​​One of the largest, prospective worldwide registries

Featured products: Ultimaster™ Sirolimus Eluting Coronary Stent System, Ultimaster™ Tansei™ Sirolimus Eluting Coronary Stent System, Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System

5/22/2019 -  

e-ultimaster.png

Low TLF rate at 1 year in a global all-comers population.

picture 2 e-ultimaster-final.png 

n= 37,198 

Bleeding BARC 3-5, CD-TLR, clinically driven target lesion revascularisation; MI, myocardial infarction; ST, definite/probable stent thrombosis; TLF, target lesion failure (composite endpoint of cardiac death, target vessel related myocardial infarction, and clinically driven target lesion revascularization); TV, target vessel; 

Cimci M et al. Heart 2022;108:1310-1318 


references.png

Complex PCI

  • e-ULTIMASTER all-comer registry enrolled more than 10,000 patients meeting complex PCI criteria 
  • Complex PCI was defined as multivessel PCI, ≥ 3 stents implanted, ≥ 3 lesions treated, bifurcation PCI with ≥ 2 stents, total stent length> 60mm and chronic total occlusion 
  • Although complex, PCI had a higher risk of ischemic and bleeding event, overall event rates for both the complex and the non-complex groups at 1 year were low

Low TLF rate with Ultimaster™ at 1 year for complex and non complex PCI subgroups in e-ULTIMASTER

bifurcation lesions

Mohamed et al. EuroIntervention 2020;16:603-612


Bifurcation lesions

  • 4,395 patients with bifurcation lesions treated with Ultimaster DES showed excellent clinical outcomes with TLF of 5.1% at 1 year 
  • Use of the proximal optimization technique (POT) was associated with a better clinical outcome with respect to TLF and TVF at 1 year due to a strong impact on the risk of TV-MI, stent thrombosis and revascularizations
​new pic4.png



e-ULTIMASTER bifurcation subgroup: propensity-matched clinical outcomes at 1 year
​Picture6LAST.png

n=4395;
CD-TLR: clinically driven target lesion revascularisation; CD-TVR: target vessel revascularization; MI, myocardial infarction; POT, proximal optimisation technique; ST, definite/probable stent thrombosis; TLF, target lesion failure (composite endpoint of cardiac death, target vessel-related myocardial infarction, and clinically driven target lesion revascularization); TV, target vessel; TVF: target vessel failure (composite endpoint of cardiac death, target vessel-related myocardial infarction, and clinically driven target vessel revascularization).

Chevalier B et al. EuroIntervention 2021;e910-e918


Multivessel disease

  • The revascularization strategy (complete versus incomplete revascularization) in multivessel disease patients treated with Ultimaster DES was assessed at 1-year follow-up
  • Complete revascularization was associated with better relief from angina, lower mortality, less target vessel failure (TVF), and lower patient oriented composite endpoint (POCE)
  • Ultimaster DES demonstrated excellent results in this complex population

e-ULTIMASTER MVD subgroup: Clinical outcomes at 1 year
​Picture5LAST.png

CD-TLR: clinically-driven target lesion revascularization; CD-TVR: clinically-driven target vessel revascularization; MI, myocardial infarction; MVD, multivessel disease; ST, definite/probable stent thrombosis; TLF, target lesion failure (composite endpoint of cardiac death, target vessel-related myocardial infarction, and clinically driven target lesion revascularization); TLR, target lesion revascularisation; ; TV, target vessel; TV-MI: target vessel myocardial infarction.


Williams T et al. Catheter Cardiovasc Interv 2022;99:961-967


​

High risk ACS 

  • The 1-year results of 14,874 STEMI or NSTEMI patients treated with Ultimaster stent showed a higher risk of cardiac death and stent thrombosis in this high hisk ACS group
  • However, the clinical outcomes in both high risk ACS and the rest of the patient group were very good

e-ULTIMASTER High risk ACS subgroup: Clinical outcomes at 1 year

last2final.png

ACS, acute coronary syndrome; CD-TVR, clinically driven target vessel revascularisation; Hr, high risk; MI, myocardial infarction; ST, definite/probable stent thrombosis; TLF, target lesion failure (composite endpoint of cardiac death, target vessel-related myocardial infarction, and clinically driven target lesion revascularization); TV, target vessel 

Laanmets P. PCR e-course 2020 


CTO

  • 1722 patients were treated for CTO with mean age (SD) of 63.8 (10.7) years 
  • Patients in the CTO group had a higher prevalence of comorbidities 
  • At 1 year, favourable clinical outcomes were observed with Ultimaster, with low incidences of cardiac death, TV-related MI, CD-TLR, and stent thrombosis

e-ULTIMASTER CTO subgroup: Clinical outcomes at 1 year
​
last1.png

CTO subgroup n=1722 

CD-TLR, clinically driven target lesion revascularisation; CTO, chronic total occlusion; MI, myocardial infarction; ST, definite /probable stent thrombosis; TLF, target lesion failure (a composite of cardiac death, target vessel myocardial infarction and clinically driven target lesion revascularization); TV, target vessel; 

Rumoroso J. PCR e-course 2020